Published in Blood on April 01, 1987
Multiple myeloma. Blood (2008) 5.88
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med (2001) 5.31
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med (2000) 4.03
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med (1997) 3.21
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med (1990) 3.21
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 2.63
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52
Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations. Leukemia (2007) 2.39
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Severe and common side-effects of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant (1998) 2.05
An unfortunate case of allergy to latex. Lancet (2000) 2.04
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00
Cytokine-mediated expansion of 5-FU-resistant peripheral blood stem cells. Exp Hematol (1995) 1.99
What's new in blood progenitor cell autotransplants? Bone Marrow Transplant (1994) 1.98
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia (2004) 1.97
Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene (1997) 1.97
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96
The EBMT activity survey: 1990-2010. Bone Marrow Transplant (2012) 1.96
Guidelines for the use of recombinant human erythropoietin. Haematologica (1995) 1.94
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med (1995) 1.94
Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med (1997) 1.93
Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia) Blood (1993) 1.93
Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica (1997) 1.88
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia (2006) 1.83
Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant (1997) 1.83
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand J Immunol (1977) 1.82
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol (2000) 1.73
Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood (1998) 1.73
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia (2005) 1.70
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Microvasculopathy in the ocular fundus after bone marrow transplantation. Ann Intern Med (1991) 1.67
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med (1999) 1.65
The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant (2011) 1.65
Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant (1990) 1.65
Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1996) 1.62
Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol (1995) 1.62
All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica (1996) 1.61
Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58
No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54
The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol (1999) 1.54
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant (2006) 1.53
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leuk Res (1997) 1.50
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood (2000) 1.49
HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol (1995) 1.49
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol (1998) 1.48
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol (1995) 1.48
Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant (2007) 1.47
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica (1997) 1.47
Preterm birth and the availability of cord blood for HPC transplantation. Transfusion (2000) 1.47
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia (2003) 1.47
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant (2011) 1.46
High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant (2002) 1.46
Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet (1985) 1.46
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.45
Antisense oligomers in chronic myeloid leukaemia. Lancet (1993) 1.45